BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Party season approaches; but first, conferences.
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
